Article info

Extended report
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Authors

  1. Correspondence to Professor Josef S Smolen, Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria; josef.smolen{at}wienkav.at, josef.smolen{at}meduniwien.ac.at
View Full Text

Citation

Smolen JS, Emery P, Ferraccioli GF, et al
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Publication history

  • Received September 19, 2013
  • Revised December 9, 2013
  • Accepted December 14, 2013
  • First published January 15, 2014.
Online issue publication 
April 02, 2015

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.